A number of other equities research analysts have also commented on the company. Morgan Stanley raised their price target on Natera from $21.00 to $41.00 and gave the stock an overweight rating in a research report on Friday, September 28th. JPMorgan Chase & Co. initiated coverage on Natera in a research report on Friday, October 5th. They set a neutral rating and a $26.00 price target on the stock. Canaccord Genuity raised their price target on Natera from $25.00 to $29.00 and gave the stock a buy rating in a research report on Thursday, August 16th. TheStreet raised Natera from a d rating to a c- rating in a research report on Thursday, August 9th. Finally, Craig Hallum lifted their target price on Natera from $23.00 to $30.00 and gave the company a buy rating in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Natera presently has a consensus rating of Buy and an average target price of $28.25.
Shares of NASDAQ NTRA traded down $3.83 during mid-day trading on Friday, reaching $16.80. 4,391,474 shares of the company’s stock were exchanged, compared to its average volume of 457,138. The firm has a market cap of $1.30 billion, a P/E ratio of -7.00 and a beta of 2.11. Natera has a twelve month low of $8.60 and a twelve month high of $29.62.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03). The business had revenue of $65.30 million for the quarter, compared to analyst estimates of $66.42 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The company’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) EPS. As a group, analysts anticipate that Natera will post -2.02 EPS for the current fiscal year.
In related news, CEO Matthew Rabinowitz sold 403,462 shares of Natera stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $24.90, for a total value of $10,046,203.80. Following the sale, the chief executive officer now owns 1,701,686 shares of the company’s stock, valued at approximately $42,371,981.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jonathan Sheena sold 166,667 shares of Natera stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total value of $3,443,340.22. Following the completion of the sale, the insider now directly owns 372,583 shares in the company, valued at approximately $7,697,564.78. The disclosure for this sale can be found here. In the last three months, insiders sold 2,014,988 shares of company stock worth $48,674,710. 13.18% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Tygh Capital Management Inc. raised its position in Natera by 32.3% in the 2nd quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock valued at $5,647,000 after buying an additional 73,301 shares during the last quarter. Prescott Group Capital Management L.L.C. acquired a new position in shares of Natera during the 2nd quarter worth approximately $572,000. EAM Investors LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $3,868,000. Sei Investments Co. acquired a new position in shares of Natera during the 2nd quarter worth approximately $928,000. Finally, Swiss National Bank increased its position in shares of Natera by 27.1% during the 2nd quarter. Swiss National Bank now owns 60,900 shares of the medical research company’s stock worth $1,146,000 after purchasing an additional 13,000 shares during the last quarter. 67.46% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Stop Order
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.